Clinical Trial Update: Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial of adjunctive SPD489 to antipsychotic therapy in adults with persistent prominent negative symptoms of schizophrenia was terminated; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SPD489

Snippet

Sponsor: Shire | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2014-05-29